Galletti F, Strazzullo P, Capaldo B, Carretta R, Fabris F, Ferrara L A, Glorioso N, Semplicini A, Mancini M
Department of Clinical and Experimental Medicine, Federico II University of Naples, Italy.
J Hypertens. 1999 Mar;17(3):439-45. doi: 10.1097/00004872-199917030-00018.
The aim of this study was to evaluate the effect of trandolapril, an angiotensin converting enzyme inhibitor, on blood pressure, forearm blood flow and insulin sensitivity in comparison with nifedipine gastrointestinal therapeutic system.
This is a multicentre, two-way parallel-group, open-label comparative study in 90 overweight hypertensive patients, who were randomly assigned to treatment for 8 weeks with either trandolapril or nifedipine. At baseline and after treatment, all patients underwent an oral glucose tolerance test, an evaluation of their metabolic profiles and a euglycaemic hyperinsulinaemic clamp test. In a subgroup of 18 patients, a forearm study was carried out.
Blood pressure fell by the second week of treatment and remained significantly reduced compared with baseline in both treatment groups. Plasma triglyceride levels were also significantly reduced after trandolapril therapy, but no significant changes occurred in the other metabolic parameters during treatment with either drug. During the euglycaemic hyperinsulinaemic clamp, whole-body glucose use was similar in the two treatment groups at baseline, and a moderate but statistically significant increase in insulin sensitivity was observed after trandolapril treatment (trandolapril: 5.0 +/- 0.2 versus 4.5 +/- 0.2 mg/kg per min; nifedipine: 4.1 +/- 0.3 versus 4.2 +/- 0.3 mg/kg per min; P < 0.05, versus baseline and trandolapril versus nifedipine treatment). Skeletal muscle glucose uptake was significantly higher after trandolapril than after nifedipine therapy (5.0 +/- 0.7 and 3.0 +/- 0.4 mg/min, respectively; P < 0.01). As forearm blood flow was similar in the two treatment groups at baseline and was unchanged after 8 weeks of therapy, skeletal muscle glucose extraction was significantly greater in the ACE inhibitor treated-group than in the nifedipine comparative group (trandolapril: baseline 21 +/- 2, treatment 24 +/- 3 mg/dl; nifedipine: baseline 18 +/- 3, treatment 16 +/- 2 mg/dl; P < 0.05, trandolapril versus nifedipine treatment).
During short-term treatment, ACE inhibition with trandolapril was able to moderately improve insulin sensitivity, in comparison with calcium blockade, and this effect appeared to be independent of the haemodynamic action of the drug.
本研究旨在比较血管紧张素转换酶抑制剂群多普利与硝苯地平胃肠道治疗系统对血压、前臂血流量及胰岛素敏感性的影响。
这是一项针对90例超重高血压患者的多中心、双向平行组、开放标签的对照研究,患者被随机分配接受群多普利或硝苯地平治疗8周。在基线期及治疗后,所有患者均接受口服葡萄糖耐量试验、代谢谱评估及正常血糖高胰岛素钳夹试验。对18例患者的亚组进行了前臂研究。
治疗第2周时血压下降,两个治疗组与基线相比血压仍显著降低。群多普利治疗后血浆甘油三酯水平也显著降低,但两种药物治疗期间其他代谢参数均无显著变化。在正常血糖高胰岛素钳夹试验中,两个治疗组在基线时全身葡萄糖利用情况相似,群多普利治疗后胰岛素敏感性有中度但具有统计学意义的增加(群多普利:5.0±0.2对4.5±0.2毫克/千克每分钟;硝苯地平:4.1±0.3对4.2±0.3毫克/千克每分钟;P<0.05,与基线相比及群多普利与硝苯地平治疗相比)。群多普利治疗后骨骼肌葡萄糖摄取显著高于硝苯地平治疗后(分别为5.0±0.7和3.0±0.4毫克/分钟;P<0.01)。由于两个治疗组在基线时前臂血流量相似,且治疗8周后未发生变化,因此血管紧张素转换酶抑制剂治疗组的骨骼肌葡萄糖摄取显著高于硝苯地平对照组(群多普利:基线21±2,治疗24±3毫克/分升;硝苯地平:基线18±3,治疗16±2毫克/分升;P<0.05,群多普利与硝苯地平治疗相比)。
在短期治疗期间,与钙通道阻滞相比,群多普利抑制血管紧张素转换酶能够适度改善胰岛素敏感性,且该作用似乎与药物的血流动力学作用无关。